Impact of Genetic Variants of Apolipoprotein E on Lipid Profile in Patients with Parkinson's Disease

Autor(es):Mostrar menos -

Gregorio, Michele L. ; Pinhel, Marcela A. S. ; Sado, Caroline L. ; Longo, Gabriela S. ; Oliveira, Fabio N. ; Amorim, Gisele S. ; Nakazone, Marcelo A. ; Florim, Greiciane M. ; Mazeti, Camila M. ; Martins, Denise P. ; Tognola, Waldir A. ; Brandao, Antonio C. ; Pinheiro Junior, Sidney ; de Godoy, Moacir F. ; Souza, Doroteia R. S.

• Tipo de documento: Artigo Científico
• Fonte: BIOMED RESEARCH INTERNATIONAL; v. 2013, p. 7-pg., 2013-01-01.

Resumo

The pathogenesis of Parkinson's disease (PD) seems to involve genetic susceptibility to neurodegeneration. APOE gene has been considered a risk factor for PD. This study aimed to evaluate the association of APOE polymorphism with PD and its influence on lipid profile. We studied 232 PD patients (PD) and 169 individuals without the disease. The studied polymorphism was analyzed by PCR/RFLP. The Fisher's exact test, chi-square, ANOVA, and t-test (P < 0.05) were applied. The APOE3/3 genotype was prevalent in PD patients and Controls (P = 0.713) followed by APOE3/4 (P = 0.772). Both groups showed recommended values for lipid profile, with increase in the values of total cholesterol and LDLc, as well as decreased values of triglycerides in PD patients compared with Controls (P < 0.05 for all of them). Increased levels of HDLc, in PD patients, were associated with the APOE3/3 versus APOE-/4 genotypes (P = 0.012). The APOE polymorphism does not distinguish PD patients from Controls, as opposed to the lipid profile alone or in association with APOE. Furthermore, a relationship between increase of HDLc levels and APOE3 in homozygous was found in PD patients only. (AU)

• Processo FAPESP: 09/17222-0 - Impacto da variante GSTP1 Alw 26I como enzima detoxificante de xenobióticos na Doença de Parkinson
• Beneficiário: Gabriela dos Santos Longo
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica
• Processo FAPESP: 08/53950-8 - Relevancia das variantes geneticas de lrrk2 e glutationa s-transferases para doenca de parkinson
• Beneficiário: Waldir Antonio Tognola
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 09/18476-6 - Impacto das Variantes Genéticas da Apolipoproteína E no Perfil Lipídico em Pacientes com Doença de Parkinson
• Beneficiário: Caroline Leiko Sado
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica